<DOC>
	<DOC>NCT00004940</DOC>
	<brief_summary>OBJECTIVES: I. Determine the long-term efficacy and safety of L-cysteine in the prevention photosensitivity in patients with erythropoietic protoporphyria.</brief_summary>
	<brief_title>Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a phase III study, lasting 3 years; 1996-1999. Patients are administered L-cysteine orally twice daily, 2 capsules with breakfast and 2 with lunch. Patients fill in questionnaires and diary sheets about their reaction to sunlight exposure, and have blood tested 3 times a year. Completion date provided represents the completion date of the grant per OOPD records</detailed_description>
	<mesh_term>Protoporphyria, Erythropoietic</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Erythropoietic protoporphyria RBC protoporphyrin greater than 50 micrograms/100 dL Prior/Concurrent Therapy At least 3 months since prior betacarotene or Lcysteine No concurrent betacarotene Patient Characteristics Fertile female patients must use effective contraception for duration of trial and for 3 weeks thereafter Not pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>erythropoietic protoporphyria</keyword>
	<keyword>inborn errors of metabolism</keyword>
	<keyword>porphyria</keyword>
	<keyword>rare disease</keyword>
</DOC>